Prosecution Insights
Prosecution Insights
7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (29%) |
| §102 only | 1 (14%) |
| §112 only | 1 (14%) |
| Double-patenting + other | 2 (29%) |
| Multi-statute (no §101) | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HEITMEIER, KENDALL NICOLE | 1 | 63.9% | +41.7% |
| VALENROD, YEVGENY | 1 | 72.6% | +25.1% |
| YOO, SUN JAE | 1 | 71.0% | +0.1% |
| TAO, BIN | 1 | 100.0% | +0.0% |
| REILLY, SOPHIA JANE | 1 | 60.6% | +49.1% |
| ANDERSON, REBECCA L | 1 | 73.3% | +23.8% |
| MOORE, SUSANNA | 1 | 67.9% | +31.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18236560 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | REILLY, SOPHIA JANE | 5d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17989103 | SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | MOORE, SUSANNA | 9d overdue |
| 18236560 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | REILLY, SOPHIA JANE | 5d |
| 18797587 | Processes For The Preparation Of Oxadiazolylamino Benzodiazepine Derivatives | HEITMEIER, KENDALL NICOLE | — |
| 18782372 | Pharmaceutical Compounds And Compositions As c-Kit Kinase Inhibitors | VALENROD, YEVGENY | — |
| 18139506 | PYRIMIDINONE-CONTAINING 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS | ANDERSON, REBECCA L | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1625 | 1 |
| 1627 | 1 |
| 1626 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18797587 | Processes For The Preparation Of Oxadiazolylamino Benzodiazepine Derivatives | HEITMEIER, KENDALL NICOLE | — | §102§103§112DP | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18782372 | Pharmaceutical Compounds And Compositions As c-Kit Kinase Inhibitors | VALENROD, YEVGENY | — | §112 | Non-Final OA | — | Pending | Jul 24, 2024 |
| 18420855 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | YOO, SUN JAE | 1621 | DPOther | Non-Final OA | — | Pending | Jan 24, 2024 |
| 18509403 | MACROCYCLIC CHALCONE-AMIDE DERIVED ANTIVIRAL AGENTS | TAO, BIN | 1625 | §102 | Non-Final OA | — | Pending | Nov 15, 2023 |
| 18236560 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | REILLY, SOPHIA JANE | 1627 | §102§103§112Other | Non-Final OA | 5d | Pending | Aug 22, 2023 |
| 18139506 | PYRIMIDINONE-CONTAINING 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS | ANDERSON, REBECCA L | 1626 | §103 | Final Rejection | — | Pending | Apr 26, 2023 |
| 17989103 | SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | MOORE, SUSANNA | 1624 | §103 | Final Rejection | 9d overdue | Pending | Nov 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial